Literature DB >> 3039492

Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.

T Andoh, K Ishii, Y Suzuki, Y Ikegami, Y Kusunoki, Y Takemoto, K Okada.   

Abstract

DNA topoisomerase I was purified to near homogeneity from a clonal line of human lymphoblastic leukemia cells, RPMI 8402, that is resistant to camptothecin, a cytotoxic alkaloid from Camptotheca acuminata, and compared with that of the parent wild-type cells. As assayed by relaxation of the supercoiled plasmid DNA and by formation of enzyme-linked DNA breaks, the purified enzyme from the resistant cells was shown to be greater than 125-fold as resistant to camptothecin as the wild-type enzyme, comparable to a cellular resistance index of about 300. Therefore, the cellular resistance appears to be due to the resistance of the enzyme. The amount of the immunoreactive enzyme protein in whole extract appeared to be reduced to less than half that of the wild-type enzyme. These results establish that DNA topoisomerase I is the cellular target of camptothecin and that DNA topoisomerase I is essential for the survival of mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3039492      PMCID: PMC298903          DOI: 10.1073/pnas.84.16.5565

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

Review 1.  Proteins that affect DNA conformation.

Authors:  J J Champoux
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

2.  Selective interruption of high molecular weight RNA synthesis in HeLa cells by camptothecin.

Authors:  H T Abelson; S Penman
Journal:  Nat New Biol       Date:  1972-05-31

3.  Lethal activity of camptothecin sodium on human lymphoma cells.

Authors:  B Drewinko; E J Freireich; J A Gottlieb
Journal:  Cancer Res       Date:  1974-04       Impact factor: 12.701

4.  Action of camptothecin on mammalian cells in culture.

Authors:  L H Li; T J Fraser; E J Olin; B K Bhuyan
Journal:  Cancer Res       Date:  1972-12       Impact factor: 12.701

5.  Studies on camptothecin-induced degradation and apparent reaggregation of DNA from L1210 cells.

Authors:  A Spataro; D Kessel
Journal:  Biochem Biophys Res Commun       Date:  1972-08-07       Impact factor: 3.575

6.  Effects of camptothecin on RNA synthesis in leukemia L1210 cells.

Authors:  D Kessel
Journal:  Biochim Biophys Acta       Date:  1971-08-26

7.  Camptothecin inhibits macromolecular synthesis in mammalian cells but not in isolated mitochondria of E. coli.

Authors:  H B Bosmann
Journal:  Biochem Biophys Res Commun       Date:  1970-12-24       Impact factor: 3.575

8.  Mechanism of inhibition of mammalian DNA topoisomerase I by heparin.

Authors:  K Ishii; S Futaki; H Uchiyama; K Nagasawa; T Andoh
Journal:  Biochem J       Date:  1987-01-01       Impact factor: 3.857

9.  Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).

Authors:  J A Gottlieb; A M Guarino; J B Call; V T Oliverio; J B Block
Journal:  Cancer Chemother Rep       Date:  1970-12

10.  Ribosome formation is blocked by camptothecin, a reversible inhibitor of RNA synthesis.

Authors:  R S Wu; A Kumar; J R Warner
Journal:  Proc Natl Acad Sci U S A       Date:  1971-12       Impact factor: 11.205

View more
  58 in total

1.  Topoisomerase I is preferentially associated with normal SV40 replicative intermediates, but is associated with both replicating and nonreplicating SV40 DNAs which are deficient in histones.

Authors:  J J Champoux
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

2.  Role of the linker domain and the 203-214 N-terminal residues in the human topoisomerase I DNA complex dynamics.

Authors:  G Chillemi; M Redinbo; A Bruselles; A Desideri
Journal:  Biophys J       Date:  2004-09-03       Impact factor: 4.033

3.  The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells.

Authors:  E Priel; S D Showalter; M Roberts; S Oroszlan; D G Blair
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

Review 4.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

5.  Contribution of topoisomerase I to conversion of single-strand into double-strand DNA breaks.

Authors:  B Kowalska-Loth; I Bubko; B Komorowska; I Szumiel; K Staron
Journal:  Mol Biol Rep       Date:  1998-01       Impact factor: 2.316

6.  Expression of circular and linearized bacterial chloramphenicol acetyltransferase genes with or without viral promoters after injection into fertilized eggs, unfertilized eggs and oocytes ofXenopus laevis.

Authors:  Yuchang Fu; Keiichi Hosokawa; Koichiro Shiokawa
Journal:  Rouxs Arch Dev Biol       Date:  1989-10

7.  Transcription-dependent degradation of topoisomerase I-DNA covalent complexes.

Authors:  Shyamal D Desai; Hui Zhang; Alexandra Rodriguez-Bauman; Jin-Ming Yang; Xiaohua Wu; Murugesan K Gounder; Eric H Rubin; Leroy F Liu
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

8.  Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c,h][1,6]naphthyridin-6-one iodide.

Authors:  Wei Feng; Mavurapu Satyanarayana; Yuan-Chin Tsai; Angela A Liu; Leroy F Liu; Edmond J LaVoie
Journal:  Eur J Med Chem       Date:  2009-02-20       Impact factor: 6.514

9.  Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites.

Authors:  H Tamura; C Kohchi; R Yamada; T Ikeda; O Koiwai; E Patterson; J D Keene; K Okada; E Kjeldsen; K Nishikawa
Journal:  Nucleic Acids Res       Date:  1991-01-11       Impact factor: 16.971

10.  Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents.

Authors:  Wei Feng; Mavurapu Satyanarayana; Liang Cheng; Angela Liu; Yuan-Chin Tsai; Leroy F Liu; Edmond J LaVoie
Journal:  Bioorg Med Chem       Date:  2008-09-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.